AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met – by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #amnog

What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?

Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel

Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the insightful discussion of Dr. Stefan Walzer and the Dutch market access expert Ron de Graaff.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #netherlands

The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?

Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium. 

Don’t miss these insights on market access for digital products!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #belgium

Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer and Esther Nzenza. Both show up important topics and to dos in order to plan and execute successfully. As a summary, local access leaders have a critical role and (obviously) R&D, Medical Affairs, Commercial, Regularity, Supply Chain all need to have a common touchpoint within market access. 

Don’t miss these insights on market access and European business strategy! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #jointHTA

What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint HTA process which is then being implemented in the respective provinces, has been introduced early 2000s. Core question remains what could be learned by European health care systems especially with respect to reimbursement and market access.

The dedicated debate is lead by Dr. Stefan Walzer who is discussing the potential learnings and take-aways with Gabriel Tremblay, a well-known Canadian Health Economic Expert. Don’t miss theses insights.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #jointHTA

Digital Health Care is already fully utilized in the US, isn’t it?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take?

In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second half of the discussion. Don’t miss these insights as well.

The US market is for sure very interesting for digital healthcare products. This podcast episode will help you to get an idea of your next steps to enter this attractive market. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #usa #diga #digital 

Does the new Italian reimbursement way allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #italy

What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.

The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #austria

What role can private health insurances play in the market access to Germany, Bastian Biermann?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Private health insurance is more important for the German healthcare system than one might think. Not only to help solving the challenges connected to the demographic changes, but also in terms of innovation. 

Dr. Stefan Walzer and the expert from the private side of the healthcare system Dr. Sebastian Biermann talking about facts and figures as well as opportunities for companies with healthcare devices or digital products. 

Take the chance to stay connected and subscribe with your favourite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de